<DOC>
	<DOC>NCT02856451</DOC>
	<brief_summary>A case series analysis of encephalitis events reported to the Sponsor for patients treated with nivolumab to assess the risk factors and outcomes of immune-mediated encephalitis.</brief_summary>
	<brief_title>Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to Nivolumab</brief_title>
	<detailed_description />
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Moderate, severe, lifethreatening or fatal encephalitis events occurring in patients treated with nivolumab and reported to the Sponsor Encephalitis cases identified through literature reviews and not reported to the Sponsor Encephalitis cases identified from companysponsored observational studies with secondary data collection Spontaneous reports not submitted directly to the Sponsor Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>